mmol/l (181 to 363 mg/100 ml) and 0-43 to 2-0 mmol/l (38 to 177 mg/ 100 ml), respectively. No patient had clinical or latent diabetes. The dose of phenytoin varied from 300 to 450 mg/day. At each examination body weight, fasting serum cholesterol and triglyceride levels, blood glucose, plasma insulin, and serum levels of phenytoin were measured, and a standard 50-g oral glucose tolerance test was performed.
Two patients were lost from the study after three months. In the nine who completed the 12-month schedule the serum phenytoin levels ranged from 10 to 63 vmol/l (2-5 to 15 9 ILg/ml). The patients maintained stable body weights throughout the study, the greatest individual change being an increase of 2 kg. The serum cholesterol levels increased by 6 to 48% (mean 19°.o; P<005) Conversion: SI to Traditional Units Cholesterol: 1 mmol/l 38 5 mg/100 ml. Triglyceride: 1 mmol/lz 88-5 mg/100 ml.
Glucose: 1 mmol/lz 18-0 mg/100 ml.
Discussion
The mechanism by which phenytoin increases the serum cholesterol level is obscure but the known pharmacological effects of the drug offer at least two possible explanations. Phenytoin decreases the level of circulating thyroid hormones including free thyroxine and triiodothyronine,2 and the increase in serum cholesterol could be due to subclinical hypothyroidism. Another explanation is based on the phenobarbitone-like effect of phenytoin on hepatic microsomal enzymes. Phenobarbitone stimulates the hepatic synthesis of cholesterol3 and increases the formation and pool size of bile acids,4 which in turn may increase the intestinal absorption of cholesterol by facilitating micelle formation.
An increase in serum cholesterol may be regarded as an untoward effect of long-term phenytoin treatment because it increases the risk of coronary heart disease. We therefore suggest that serum cholesterol should be regularly checked in patients undergoing such treatment.
The lack of deterioration in glucose tolerance may have been due to the relatively small doses of phenytoin used. The mean plasma insulin response to oral glucose also remained unchanged during treatment, though a clear tendency of a diminishing insulin secretion occurred, particularly in patients with high pretreatment levels. This observation agreed with the experience of Stambaugh and Tucker.5 This study was aided by project grant 01190714 from the Finnish Medical Research Council (Academy of Finland). We thank Mrs. SirkkaLiisa Runeberg for technical help. Enteric-coated aspirin is claimed not to irritate gastric mucosa. We report a case of fatal gastric perforation due to Safapryn. Safapryn consists of a sugar-coated tablet containing 250 mg of paracetamol outside an enteric-coated core of 300 mg of aspirin. The enteric coat is cellulose acetate phthallate, which disintegrates when the pH rises to 6 8.
